Clinical trial
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
NCT00047801 is registered in ClinicalTrials.gov with Telik as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
- Lead sponsor
- Telik
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2002
- Completion date
- September 30, 2004
- Enrollment
- 28
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.